Phase 2 N=27 Single Dose Intranasal Oxytocin and Cognitive Effects in Autism
Autism Spectrum Disorders
Primary: Reading the Mind in the Eyes Task (RMET) — 18.07; 18.08; 17.86; 18.09 total raw score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=28 Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
Plaque Psoriasis
Primary: The Primary Outcome Measure Will be to Evaluate Change in Aberrant Inflammatory Profiles of Activated Blood Monocytes (Aberrant-monocyte Endotype Patients (AM-endotype)…
Phase 2 N=399 Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants
Clostridium Difficile Immunisation · Diphtheria · Diphtheria Immunisation
Primary: Number of Pregnant Women Reporting Related Serious Adverse Events (SAEs) and Unrelated SAEs — 0; 0; 20; 10 Participants
Phase 2 N=23 Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Toxicities — 0 Participants
Phase 2 N=102 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Erythropoietic Protoporphyria (EPP)
Primary: Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week…
Phase 2 N=23 Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Blastoid Variant Mantle Cell Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Follicular Lymphoma
Primary: Progression Free Survival Probability at 12-month Post HCT — 0.80 probability
Phase 2 N=213 A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
End-stage Renal Disease (ESRD)
Primary: Number of Participants With Major Bleeding (MB) and Clinically Relevant Non-Major Bleeding (CRNMB) — 3; 2; 3; 3 Participants
Phase 2 N=105 Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
Neoplasms
Primary: Overall Survival — 8.2; 7.8 Months
Phase 2 N=3 Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma
Primary: Objective Response Rate (ORR) — 2; 0 Participants
Phase 2 N=15 COVID-19 Study of Safety and Tolerability of Alvelestat
Covid19
Primary: Numbers and % of Subjects Who Experience at Least 1 Treatment-emergent Adverse Event — 3; 5 Participants
Phase 2 N=36 Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis
Blepharitis
Primary: COHORT 1 and 2 COMBINED: Mean Change From Baseline to Day 14 in the Composite (Sum) Score of Signs & Symptoms of Blepharitis — -2.0; -1.2 units on a scale — p=0.0471
Phase 2 N=19 Electrical Stimulation for Critically Ill Post-Covid-19 Patients
COVID-19 · Muscle Atrophy · Muscle Weakness
Primary: Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 363.04; 359.55 miliVolts
Phase 2 N=96 Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19
Covid-19
Primary: Percentage of Subjects Alive and Free of Respiratory Failure at Day 28 — 40; 38 Participants
Phase 2 N=33 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Metastatic Melanoma
Primary: Number of Participants With Treatment-related Grade 3-5 Adverse Events in Arm 1N and Arm 1P — 0; 2; 0; 0 Participants
Phase 2 N=26 A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx
Hypertension
Primary: Percent Change From Baseline in Plasma Angiotensinogen (AGT) at Day 57 Compared to Placebo — -3.4; -67.4 percent change — p=< 0.001